Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Targacept NNR Drug Development Is Smokin’ After GSK Cash Infusion

This article was originally published in The Pink Sheet Daily

Executive Summary

Glaxo partners with Targacept in potential $1.5 billion deal on neuronal nicotinic receptor therapeutics for pain, smoking cessation, obesity, addiction and Parkinson’s.

You may also be interested in...



Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.

Targacept CEO J. Donald DeBethizy – An Interview With “The Pink Sheet” DAILY (Part 2 of 2)

DeBethizy discusses the firm’s deal with GlaxoSmithKline and what lies ahead for the Raleigh, N.C.-based company.

Targacept/GSK’s Nicotinic Receptor Modulator Fails Phase II Pain Study

Experimental pain killer performed no better than placebo, failing a proof-of-concept study for post-operative pain.

Related Content

Topics

UsernamePublicRestriction

Register

PS066388

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel